Name: Urea Cycle Disorder Treatment Market Size, Share, Industry, Forecast and outlook (2023-2030)
Brand: DataM Intelligence
SKU: PH3491
Price: 4350 USD
Availability: InStock

Urea Cycle Disorder Treatment Market Size Share & Forecast 2023-2030

Urea Cycle Disorder Treatment Market Size, Share, Industry, Forecast and outlook (2023-2030)

<h2>Global Urea Cycle Disorder Treatment Market&nbsp;is segmented By Treatment Type&nbsp;(Glycerol Phenylbutyrate, Amino Acid Supplements, Sodium Phenylbutyrate, Sodium Benzoate, Others (Low Protein Diet, Carglumic acid, etc.)), By Enzyme Deficiency Type&nbsp;(OTC &ndash; Ornithine Transcarbamylase, AS &ndash; Argininosuccinate Synthetase (citrullinemia), AG &ndash; Arginase, AL &ndash; Argininosuccinate Lyase, CPS1 &ndash; Carbamoyl Phosphate Synthase, NAGS &ndash; N-acetylglutamate Synthase), By Distribution Channel&nbsp;(Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region&nbsp;(North America, Europe, South America, Asia Pacific, Middle East,&nbsp;and Africa) &ndash; Share, Size, Outlook, and Opportunity Analysis, 2022-2029</h2>

&nbsp;

<h2>Market Overview</h2>

<blockquote>
The global urea cycle disorders treatment market size was valued US$ XX billion in 2022&nbsp;and is estimated to reach US$ XX billion by 2029, growing at a CAGR of XX % during the forecast period (2022-2029).&nbsp;&nbsp;
</blockquote>

A urea cycle disorder is a genetic disorder caused by a mutation that results in a deficiency of one of the six enzymes in the urea cycle. These enzymes are responsible for removing ammonia from the bloodstream. The treatment of urea cycle disorders consists of dietary management to limit ammonia production. A liver transplant can be an effective treatment for urea cycle disorder for the proper functioning of the urea cycle.

<h2>Market Dynamics</h2>

The urea cycle disorders treatment market growth is driven by the increasing incidence of urea cycle disorders; rising initiatives by key players operating in the market for supporting patients suffering from UCD are the major driving factors of the market.

Increasing incidence of urea cycle disorders, is expected to drive the growth in the forecast period

According to reports published by the CDC (Centers for Disease Control and Prevention), the anticipated incidence of UCD is 1 in 8500 births. Because many urea cycle disorders remain undiagnosed and infants born with the disorders die without a definitive diagnosis, the exact incidence of these cases is unknown and underestimated. It is believed that up to 20% of Sudden Infant Death Syndrome (SIDS) cases may be attributed to an undiagnosed inborn error of metabolism such as a urea cycle disorder expected to drive the urea cycle disorders treatment market forecast period. For instance, according to the article published in the Orphanet Journal of Rare Diseases in June 2017, the estimated prevalence of ornithine transcarbamylase deficiency ranges between 1/56,500 to 1/113,000 live births across the world.

Growing initiatives by key players and government, is expected to drive the growth in the forecast period

The rising initiatives by key players as well as governments for supporting patients suffering from UCD. For instance, in March 2017, Horizon Pharma plc launched UCD in Common, an initiative for people suffering from urea cycle disorder, to offer supportive, educational, and interactive resources to the patients living with UCD, their families, caregivers, and healthcare professionals.

Challenges in diagnosing and managing adult patients with urea cycle disorders in long-term therapies is likely to hinder the market growth

Early diagnosis is critical for effective treatment and to prevent long-term complications of hyperammonemia. The challenges of management of adults include, for example:

<ol>
	<li>Poor compliance to dietary and medical treatment, which can result in recurrent hospital admissions</li>
	<li>Severe neurological dysfunction</li>
	<li>The management of pregnancy and the postpartum period</li>
	<li>Access to multidisciplinary care peri-operatively</li>
</ol>

COVID-19 Impact Analysis

Following the COVID-19 outbreak in December 2019, the disease has spread to over 100 countries globally, and the World Health Organization has declared it a public health emergency. According to the World Health Organization&rsquo;s report, the coronavirus (COVID-19) manifestation has resulted in more than 52.7 million infected individuals worldwide as of November 13, 2020.

The coronavirus (COVID-19) pandemic and resulting lockdown in various countries across the globe have impacted major companies&#39; financial status in the urea cycle disorders treatment market. The private healthcare sector is one of the sectors, which the COVID-19 pandemic has majorly impacted. The pandemic has negatively impacted the global urea cycle disorders treatment market in various aspects such as research and development, production, and supply of medicines. The pandemic has also affected the growth of pharmaceutical businesses of various companies across the globe due to lockdowns implemented by governments of several countries.

<h2>Market Segment Analysis</h2>

The glycerol phenylbutyrate segment is expected to hold largest share in this market segment

Glycerol phenylbutyrate (Ravicti) is an adjunctive therapy for chronic management of patients with urea cycle disorders. Ravicti is the first licensed oral liquid of phenylbutyrate and shares the same mechanism of action and metabolic pathway as sodium phenylbutyrate. Ravicti provides an alternative option in a formulation that may reduce the substantial treatment burden and unpleasant taste and odor associated with sodium phenylbutyrate.

The Ornithine transcarbamylase segment is expected to hold largest share in this market segment

Ornithine transcarbamylase deficiency is the most common urea cycle disorder in humans. It is an inherited disorder that causes toxic levels of ammonia to build up in the blood. Ornithine transcarbamylase, the defective enzyme in this disorder, is the final enzyme in the proximal portion of the urea cycle. For instance, according to the article published in the Orphanet Journal of Rare Diseases in June 2017, the estimated prevalence of ornithine transcarbamylase deficiency ranges between 1/56,500 to 1/113,000 live births across the world.

The hospital pharmacies segment is expected to hold largest share in this market segment

The hospital pharmacies held the largest share in the interleukin inhibitors market. This is mainly owing to increasing number of patients suffering from conditions which are treated in hospitals equipped with advanced infrastructure and adequate facilities. Moreover, growing number of hospitals along with adequate reimbursement policies is also contributing to the growth of this segment.

<h2>Geographical Analysis</h2>

North America region holds the largest market share of global urea cycle disorders treatment market 

North America region is expected to hold a dominant position in the global urea cycle disorders treatment market over the forecast period, owing to increasing research and development by academic institutes in gene therapy to treat urea cycle disorders.

For instance, in March 2019, the University of Calgary Cumming School of Medicine (CSM) and Alberta Health Services (AHS) collaboratively initiated the clinical trial study on the treatment of urea cycle disorders with the help of gene therapy. The clinical trial study was conducted at the Clinical Trials Unit (CTU) at the Foothills Medical Centre (FMC), a hospital in Canada.

Moreover, due to long-term therapy, patients may suffer from some complications, including fussiness, sleepiness or sluggishness, vomiting, low body temperature, problems with posture, seizures, and others. Thus, such complications of long-term therapy are expected to hinder the market growth over the forecast period.

<h2>Competitive Landscape</h2>

The global urea cycle disorders treatment market is sightly competitive with presence of global companies.&nbsp; Some of the key players which are contributing to the growth of the market include Horizon Pharma plc. Lucane Pharma, Recordati Rare Diseases Inc., Synlogic, Acer Therapeutics, Ultragenyx Pharmaceutical Inc., Aeglea BioTherapeutics, Arcturus Therapeutics Holdings, Orpharma Pty Ltd, Bausch Health Companies, Inc. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the market globally.

Urea Cycle Disorders Treatment Market Key Companies to Watch

Recordati Rare Diseases Inc

Overview: Recordati Rare Diseases is a pharmaceutical company that provides treatment for patients with rare diseases. Created in 1990, Recordati Rare Diseases is one of the most active companies in the field of rare diseases.

Our specialty rare disease products are marketed directly by Recordati Rare Diseases in Europe, the Middle East, the U.S.A., Canada, Russia, Japan and Australia, in some Latin American countries, and through selected partners in other parts of the world.&nbsp;Recordati founded in Correggio, Reggio Emilia, Italy.

Product Portfolio: The Company&rsquo;s portfolio comprised of include Hyperammonaemia, Acromegaly, Rare cancers, Cushing&rsquo;s disease and syndrome, Wilson&rsquo;s disease, Cystic fibrosis etc.

Why Purchase the Report?

<ul>
	<li>Visualize the composition of the urea cycle disorders treatment market segmentation by treatment type, enzyme deficiency type, distribution channel and region highlighting the key commercial assets and players.</li>
	<li>Identify commercial opportunities in urea cycle disorders treatment market by analyzing trends and co-development deals.</li>
	<li>Excel data sheet with thousands of data points of urea cycle disorders treatment market - level 4/5 segmentation.</li>
	<li>PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.</li>
	<li>Product mapping in excel for the key product of all major market players</li>
</ul>

The global urea cycle disorders treatment market report would provide an access to an approx. 61 market data table, 57 figures and 200 pages.&nbsp; 

Target Audience

<ul>
	<li>Service Providers/ Buyers</li>
	<li>Industry Investors/Investment Bankers</li>
	<li>Education &amp; Research Institutes</li>
	<li>Research Professionals</li>
	<li>Emerging Companies</li>
	<li>Manufacturers</li>
</ul>

<h2 style="background:#eeeeee; border:1px solid #cccccc; padding:5px 10px">Table of Contents</h2>

<ol>
	<li>
	<h3>Methodology and Scope</h3>

	<ol>
		<li>Research Methodology</li>
		<li>Research Objective and Scope of the Report</li>
	</ol>
	</li>
	<li>
	<h3>Market Definition and Overview</h3>
	</li>
	<li>
	<h3>Executive Summary</h3>

	<ol>
		<li>Market Snippet by Treatment Type</li>
		<li>Market Snippet by Distribution Channel</li>
		<li>Market Snippet by Enzyme Deficiency Type</li>
		<li>Market Snippet by Region</li>
	</ol>
	</li>
	<li>
	<h3>Market Dynamics</h3>

	<ol>
		<li>Market Impacting Factors
		<ol>
			<li>Drivers
			<ol>
				<li>Increasing incidence of urea cycle disorders</li>
				<li>Growing initiatives by key players and government</li>
			</ol>
			</li>
			<li>Restraints:
			<ol>
				<li>Challenges in diagnosing and managing adult patients with urea cycle disorders in long-term therapies</li>
			</ol>
			</li>
			<li>Opportunity</li>
			<li>Impact Analysis</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>
	<h3>Industry Analysis</h3>

	<ol>
		<li>Porter&#39;s Five Forces Analysis</li>
		<li>PEST Analysis</li>
		<li>Supply Chain Analysis</li>
		<li>Pricing Analysis</li>
		<li>Regulatory Analysis</li>
		<li>Reimbursement Analysis</li>
		<li>Unmet Needs</li>
	</ol>
	</li>
	<li>
	<h3>COVID-19 Analysis</h3>

	<ol>
		<li>Analysis of Covid-19 on the Market
		<ol>
			<li>Before COVID-19 Market Scenario</li>
			<li>Present COVID-19 Market Scenario</li>
			<li>After COVID-19 or Future Scenario</li>
		</ol>
		</li>
		<li>Pricing Dynamics Amid Covid-19</li>
		<li>Demand-Supply Spectrum</li>
		<li>Government Initiatives Related to the Market During Pandemic</li>
		<li>Manufacturers Strategic Initiatives</li>
		<li>Conclusion&nbsp;</li>
	</ol>
	</li>
	<li>
	<h3>By Treatment Type</h3>

	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type</li>
			<li>Market Attractiveness Index, By Treatment Type</li>
		</ol>
		</li>
		<li>&nbsp;Glycerol Phenylbutyrate*
		<ol>
			<li>Introduction</li>
			<li>Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028</li>
		</ol>
		</li>
		<li>Amino Acid Supplements</li>
		<li>Sodium Phenylbutyrate</li>
		<li>Sodium Benzoate</li>
		<li>Others (Low Protein Diet, Carglumic acid, etc.)</li>
	</ol>
	</li>
	<li>
	<h3>By Enzyme Deficiency Type</h3>

	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Enzyme Deficiency Type Segment</li>
			<li>Market Attractiveness Index, By Enzyme Deficiency Type Segment</li>
		</ol>
		</li>
		<li>&nbsp;OTC &ndash; Ornithine Transcarbamylase*
		<ol>
			<li>Introduction</li>
			<li>Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028</li>
		</ol>
		</li>
		<li>AS &ndash; Argininosuccinate Synthetase (citrullinemia)</li>
		<li>AG &ndash; Arginase</li>
		<li>AL &ndash; Argininosuccinate Lyase</li>
		<li>CPS1 &ndash; Carbamoyl Phosphate Synthase</li>
		<li>NAGS &ndash; N-acetylglutamate Synthase</li>
	</ol>
	</li>
	<li>
	<h3>By Distribution Channel</h3>

	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution channel Segment</li>
			<li>Market Attractiveness Index, By Distribution channel Segment</li>
		</ol>
		</li>
		<li>&nbsp;Hospital Pharmacies*
		<ol>
			<li>Introduction</li>
			<li>Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028</li>
		</ol>
		</li>
		<li>Retail Pharmacies</li>
		<li>Online Pharmacies</li>
	</ol>
	</li>
	<li>
	<h3>By Region</h3>

	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028, By Region</li>
			<li>Market Attractiveness Index, By Region</li>
		</ol>
		</li>
		<li>North America
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Enzyme Deficiency Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>U.S.</li>
				<li>Canada</li>
				<li>Mexico</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>Europe
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Enzyme Deficiency Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>Germany</li>
				<li>U.K.</li>
				<li>France</li>
				<li>Italy</li>
				<li>Spain</li>
				<li>Rest of Europe</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>South America
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Enzyme Deficiency Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>Brazil</li>
				<li>Argentina</li>
				<li>Rest of South America</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>Asia Pacific
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Enzyme Deficiency Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>China</li>
				<li>India</li>
				<li>Japan</li>
				<li>Australia</li>
				<li>Rest of Asia Pacific</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>Middle East and Africa
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Enzyme Deficiency Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>
	<h3>Competitive Landscape</h3>

	<ol>
		<li>Key Developments and Strategies</li>
		<li>Company Share Analysis</li>
		<li>Product Benchmarking</li>
		<li>Key Companies to Watch</li>
		<li>Company with disruptive technology</li>
		<li>Start Up Companies</li>
	</ol>
	</li>
	<li>
	<h3>Company Profiles</h3>

	<ol>
		<li>Recordati Rare Diseases Inc*
		<ol>
			<li>Company Overview</li>
			<li>Product Portfolio and Description</li>
			<li>Key Highlights</li>
			<li>Financial Overview</li>
		</ol>
		</li>
		<li>Horizon Pharma plc</li>
		<li>Lucane Pharma</li>
		<li>Synlogic</li>
		<li>Acer Therapeutics</li>
		<li>Ultragenyx Pharmaceutical Inc</li>
		<li>Aeglea BioTherapeutics</li>
		<li>Arcturus Therapeutics Holdings</li>
		<li>Orpharma Pty Ltd</li>
		<li>Bausch Health Companies, Inc(*LIST NOT EXHAUSTIVE)</li>
	</ol>
	</li>
	<li>
	<h3>DataM Intelligence&nbsp;</h3>

	<ol>
		<li>Appendix</li>
		<li>About Us and Services</li>
		<li>Contact Us</li>
	</ol>
	</li>
</ol>

<h2 style="background:#eeeeee; border:1px solid #cccccc; padding:5px 10px">List of Tables &amp; Figures</h2>

List of Tables

Table 1 Global Urea Cycle Disorder Treatment Market Value, By Treatment Type, 2021,2024 &amp; 2029 ($ Million)

Table 2 Global Urea Cycle Disorder Treatment Market Value, By Enzyme Deficiency Type, 2021,2024 &amp; 2029 ($ Million)

Table 3 Global Urea Cycle Disorder Treatment Market Value, By Distribution Channel, 2021,2024 &amp; 2029 ($ Million)

Table 4 Global Urea Cycle Disorder Treatment Market Value, By Region, 2021,2024 &amp; 2029 ($ Million)

Table 5 Global Urea Cycle Disorder Treatment Market Value, By Treatment Type, 2021,2024 &amp; 2029 ($ Million)

Table 6 Global Urea Cycle Disorder Treatment Market Value, By Treatment Type, 2018-2029 ($ Million)

Table 7 Global Urea Cycle Disorder Treatment Market Value, By Enzyme Deficiency Type, 2021,2024 &amp; 2029 ($ Million)

Table 8&nbsp;&nbsp;&nbsp;&nbsp; Global Urea Cycle Disorder Treatment Market Value, By Enzyme Deficiency Type, 2018-2029 ($ Million)

Table 9 Global Urea Cycle Disorder Treatment Market Value, By Distribution Channel, 2021,2024 &amp; 2029 ($ Million)

Table 10&nbsp;&nbsp; Global Urea Cycle Disorder Treatment Market Value, By Distribution Channel, 2018-2029 ($ Million)

Table 11&nbsp;&nbsp;&nbsp; Global Urea Cycle Disorder Treatment Market Value, By Region, 2021,2024 &amp; 2029 ($ Million)

Table 12&nbsp;&nbsp; Global Urea Cycle Disorder Treatment Market Value, By Region, 2018-2029 ($ Million)

Table 13&nbsp;&nbsp; North America Urea Cycle Disorder Treatment Market Value, By Treatment Type, 2018-2029 ($ Million)

Table 14&nbsp;&nbsp; North America Urea Cycle Disorder Treatment Market Value, By Enzyme Deficiency Type, 2018-2029 ($ Million)

Table 15&nbsp;&nbsp; North America Urea Cycle Disorder Treatment Market Value, By Distribution Channel, 2018-2029 ($ Million)

Table 16&nbsp;&nbsp; North America Urea Cycle Disorder Treatment Market Value, By Country, 2018-2029 ($ Million)

Table 17&nbsp;&nbsp;&nbsp; South America Urea Cycle Disorder Treatment Market Value, By Treatment Type, 2018-2029 ($ Million)

Table 18&nbsp;&nbsp; South America Urea Cycle Disorder Treatment Market Value, By Enzyme Deficiency Type, 2018-2029 ($ Million)

Table 19&nbsp;&nbsp; South America Urea Cycle Disorder Treatment Market Value, By Distribution Channel, 2018-2029 ($ Million)

Table 20&nbsp;&nbsp; South America Urea Cycle Disorder Treatment Market Value, By Country, 2018-2029 ($ Million)

Table 21&nbsp;&nbsp; Europe Urea Cycle Disorder Treatment Market Value, By Treatment Type, 2018-2029 ($ Million)

Table 22&nbsp;&nbsp; Europe Urea Cycle Disorder Treatment Market Value, By Enzyme Deficiency Type, 2018-2029 ($ Million)

Table 23&nbsp;&nbsp; Europe Urea Cycle Disorder Treatment Market Value, By Distribution Channel, 2018-2029 ($ Million)

Table 24&nbsp;&nbsp; Europe Urea Cycle Disorder Treatment Market Value, By Country, 2018-2029 ($ Million)

Table 25&nbsp;&nbsp; Asia-Pacific Urea Cycle Disorder Treatment Market Value, By Treatment Type, 2018-2029 ($ Million)

Table 26&nbsp;&nbsp; Asia-Pacific Urea Cycle Disorder Treatment Market Value, By Enzyme Deficiency Type, 2018-2029 ($ Million)

Table 27&nbsp;&nbsp; Asia-Pacific Urea Cycle Disorder Treatment Market Value, By Distribution Channel, 2018-2029 ($ Million)

Table 28&nbsp;&nbsp; Asia-Pacific Urea Cycle Disorder Treatment Market Value, By Country, 2018-2029 ($ Million)

Table 29&nbsp;&nbsp; Middle East &amp; Africa Urea Cycle Disorder Treatment Market Value, By Treatment Type, 2018-2029 ($ Million)

Table 30&nbsp;&nbsp; Middle East &amp; Africa Urea Cycle Disorder Treatment Market Value, By Enzyme Deficiency Type, 2018-2029 ($ Million)

Table 31&nbsp;&nbsp; Middle East &amp; Africa Urea Cycle Disorder Treatment Market Value, By Distribution Channel, 2018-2029 ($ Million)

Table 32&nbsp;&nbsp; Recordati Rare Diseases Inc: Overview

Table 33&nbsp;&nbsp; Recordati Rare Diseases Inc: Product Portfolio

Table 34&nbsp;&nbsp; Recordati Rare Diseases Inc: Key Developments

Table 35&nbsp;&nbsp; Horizon Pharma plc: Overview

Table 36&nbsp;&nbsp; Horizon Pharma plc: Product Portfolio

Table 37&nbsp;&nbsp; Horizon Pharma plc: Key Developments

Table 38&nbsp;&nbsp; Lucane Pharma: Overview

Table 39&nbsp;&nbsp; Lucane Pharma: Product Portfolio

Table 40&nbsp;&nbsp; Lucane Pharma: Key Developments

Table 41&nbsp;&nbsp; Synlogic: Overview

Table 42&nbsp;&nbsp; Synlogic: Product Portfolio

Table 43&nbsp;&nbsp; Synlogic: Key Developments

Table 44&nbsp;&nbsp; Acer Therapeutics: Overview

Table 45&nbsp;&nbsp; Acer Therapeutics: Product Portfolio

Table 46&nbsp;&nbsp; Acer Therapeutics: Key Developments

Table 47&nbsp;&nbsp; Ultragenyx Pharmaceutical Inc: Overview

Table 48&nbsp;&nbsp; Ultragenyx Pharmaceutical Inc: Product Portfolio

Table 49&nbsp;&nbsp; Ultragenyx Pharmaceutical Inc: Key Developments

Table 50&nbsp;&nbsp; Aeglea BioTherapeutics: Overview

Table 51&nbsp;&nbsp; Aeglea BioTherapeutics: Product Portfolio

Table 52&nbsp;&nbsp; Aeglea BioTherapeutics: Key Developments

Table 53&nbsp;&nbsp; Arcturus Therapeutics Holdings: Overview

Table 54&nbsp;&nbsp; Arcturus Therapeutics Holdings: Product Portfolio

Table 55&nbsp;&nbsp; Arcturus Therapeutics Holdings: Key Developments

Table 56&nbsp;&nbsp; Orpharma Pty Ltd: Overview

Table 57&nbsp;&nbsp; Orpharma Pty Ltd: Product Portfolio

Table 58&nbsp;&nbsp; Orpharma Pty Ltd: Key Developments

Table 59&nbsp;&nbsp; Bausch Health Companies, Inc: Overview

Table 60&nbsp;&nbsp; Bausch Health Companies, Inc: Product Portfolio

Table 61&nbsp;&nbsp; Bausch Health Companies, Inc: Key Developments

&nbsp;

List of Figures

Figure 1&nbsp;&nbsp;&nbsp; Global Urea Cycle Disorder Treatment Market Share, By Treatment Type, 2021 &amp; 2029 (%)

Figure 2&nbsp;&nbsp; Global Urea Cycle Disorder Treatment Market Share, By Enzyme Deficiency Type, 2021 &amp; 2029 (%)

Figure 3&nbsp;&nbsp; Global Urea Cycle Disorder Treatment Market Share, By Distribution Channel, 2021 &amp; 2029 (%)

Figure 4&nbsp;&nbsp; Global Urea Cycle Disorder Treatment Market Share, By Region, 2021 &amp; 2029 (%)

Figure 5&nbsp;&nbsp; Global Urea Cycle Disorder Treatment Market Value, 2018-2029 ($ Million)

Figure 6&nbsp;&nbsp; Global Urea Cycle Disorder Treatment Market Y-o-Y Growth, By Treatment Type, 2021-2029 (%)

Figure 7&nbsp;&nbsp;&nbsp; Amino Acid Supplements: Global Urea Cycle Disorder Treatment Market Value, 2018-2029 ($ Million)

Figure 8&nbsp;&nbsp; Sodium Phenylbutyrate: Global Urea Cycle Disorder Treatment Market Value, 2018-2029 ($ Million)

Figure 9&nbsp;&nbsp; Glycerol Phenylbutyrate: Global Urea Cycle Disorder Treatment Market Value, 2018-2029 ($ Million)

Figure 10 Sodium Benzoate: Global Urea Cycle Disorder Treatment Market Value, 2018-2029 ($ Million)

Figure 11&nbsp; Others (Low Protein Diet, Carlumab acid, etc.): Global Urea Cycle Disorder Treatment Market Value, 2018-2029 ($ Million)

Figure 12 Global Urea Cycle Disorder Treatment Market Y-o-Y Growth, By Enzyme Deficiency Type, 2021-2029 (%)

Figure 13 OTC &ndash; Ornithine Transcarboxylase: Global Urea Cycle Disorder Treatment Market Value, 2018-2029 ($ Million)

Figure 14 AS &ndash; Argininosuccinate Synthetase (citrullinemia): Global Urea Cycle Disorder Treatment Market Value, 2018-2029 ($ Million)

Figure 15 AG &ndash; Arginase: Global Urea Cycle Disorder Treatment Market Value, 2018-2029 ($ Million)

Figure 16 AL &ndash; Argininosuccinate Lyase: Global Urea Cycle Disorder Treatment Market Value, 2018-2029 ($ Million)

Figure 17&nbsp; CPS1 &ndash; Carbamoyl Phosphate Synthase: Global Urea Cycle Disorder Treatment Market Value, 2018-2029 ($ Million)

Figure 18 NAGS &ndash; N-acetylglutamate Synthase: Global Urea Cycle Disorder Treatment Market Value, 2018-2029 ($ Million)

Figure 19 Global Urea Cycle Disorder Treatment Market Y-o-Y Growth, By Distribution Channel, 2021-2029 (%)

Figure 20 Hospital Pharmacies: Global Urea Cycle Disorder Treatment Market Value, 2018-2029 ($ Million)

Figure 21 Retail Pharmacies: Global Urea Cycle Disorder Treatment Market Value, 2018-2029 ($ Million)

Figure 22 Online Pharmacies: Global Urea Cycle Disorder Treatment Market Value, 2018-2029 ($ Million)

Figure 23 Global Urea Cycle Disorder Treatment Market Y-o-Y Growth, By Region, 2021-2029 (%)

Figure 24 North America Urea Cycle Disorder Treatment Market Value, 2018-2029 ($ Million)

Figure 25 North America Urea Cycle Disorder Treatment Market Share, By Treatment Type, 2021 &amp; 2029 (%)

Figure 26 North America Urea Cycle Disorder Treatment Market Share, By Enzyme Deficiency Type, 2021 &amp; 2029 (%)

Figure 27 North America Urea Cycle Disorder Treatment Market Share, By Distribution Channel, 2021 &amp; 2029 (%)

Figure 28 North America Urea Cycle Disorder Treatment Market Share, By Country, 2021 &amp; 2029 (%)

Figure 29 South America Urea Cycle Disorder Treatment Market Value, 2018-2029 ($ Million)

Figure 30 South America Urea Cycle Disorder Treatment Market Share, By Treatment Type, 2021 &amp; 2029 (%)

Figure 31 South America Urea Cycle Disorder Treatment Market Share, By Enzyme Deficiency Type, 2021 &amp; 2029 (%)

Figure 32 South America Urea Cycle Disorder Treatment Market Share, By Distribution Channel, 2021 &amp; 2029 (%)

Figure 33 South America Urea Cycle Disorder Treatment Market Share, By Country, 2021 &amp; 2029 (%)

Figure 34 Europe Urea Cycle Disorder Treatment Market Value, 2018-2029 ($ Million)

Figure 35 Europe Urea Cycle Disorder Treatment Market Share, By Treatment Type, 2021 &amp; 2029 (%)

Figure 36 Europe Urea Cycle Disorder Treatment Market Share, By Enzyme Deficiency Type, 2021 &amp; 2029 (%)

Figure 37 Europe Urea Cycle Disorder Treatment Market Share, By Distribution Channel, 2021 &amp; 2029 (%)

Figure 38 Europe Urea Cycle Disorder Treatment Market Share, By Country, 2021 &amp; 2029 (%)

Figure 39 Asia-Pacific Urea Cycle Disorder Treatment Market Value, 2018-2029 ($ Million)

Figure 40 Asia-Pacific Urea Cycle Disorder Treatment Market Share, By Treatment Type, 2021 &amp; 2029 (%)

Figure 41 Asia-Pacific Urea Cycle Disorder Treatment Market Share, By Enzyme Deficiency Type, 2021 &amp; 2029 (%)

Figure 42 Asia-Pacific Urea Cycle Disorder Treatment Market Share, By Distribution Channel, 2021 &amp; 2029 (%)

Figure 43 Asia-Pacific Urea Cycle Disorder Treatment Market Share, By Country, 2021 &amp; 2029 (%)

Figure 44 Middle East &amp; Africa Urea Cycle Disorder Treatment Market Value, 2018-2029 ($ Million)

Figure 45 Middle East &amp; Africa Urea Cycle Disorder Treatment Market Share, By Treatment Type, 2021 &amp; 2029 (%)

Figure 46 Middle East &amp; Africa Urea Cycle Disorder Treatment Market Share, By Enzyme Deficiency Type, 2021 &amp; 2029 (%)

Figure 47 Middle East &amp; Africa Urea Cycle Disorder Treatment Market Share, By Distribution Channel, 2021 &amp; 2029 (%)

Figure 48 Recordati Rare Diseases Inc: Financials

Figure 49 Horizon Pharma plc: Financials

Figure 50 Lucane Pharma: Financials

Figure 51 Synlogic: Financials

Figure 52 Acer Therapeutics: Financials

Figure 53 Ultragenyx Pharmaceutical Inc: Financials

Figure 54 Aeglea BioTherapeutics: Financials

Figure 55 Arcturus Therapeutics Holdings: Financials

Figure 56 Orpharma Pty Ltd: Financials

Figure 57 Bausch Health Companies, Inc: Financials

&nbsp;